DISCOUNT ZERTIFIKAT - NOVO NORDISK ADR B | Real-time Bid/Ask 01:05:07 2024-07-01 pm EDT | ||
| 108.3 EUR / 108.32 EUR | +0.52% |
|
| Current month | +3.95% | ||
| 1 month | +4.63% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-01 | 108 | +0.21% |
| 24-06-28 | 107.8 | -0.19% |
| 24-06-27 | 108 | -0.18% |
| 24-06-26 | 108.2 | -0.30% |
| 24-06-25 | 108.5 | +1.28% |
Delayed Quote Börse Stuttgart
Last update July 01, 2024 at 11:01 am EDT
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME85RV |
| ISIN | DE000ME85RV3 |
| Date issued | 2024-02-05 |
| Maturity | 2025-06-20 (354 Days) |
| Parity | 1 : 1 |
| Emission price | 95.89 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 108.8 € |
|---|---|
| Lowest since issue | 94.34 € |
| Spread | 0.02 € |
| Spread % | 0.02% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Certificates
- Certificat
